Vijay Radhakrishnan
Overview
Explore the profile of Vijay Radhakrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
88
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Radhakrishnan V, Golla U, Kudva A
Life (Basel)
. 2024 Apr;
14(4).
PMID: 38672732
The clinical signs of multiple myeloma, a plasma cell (PC) dyscrasia, include bone loss, renal damage, and paraproteinemia. It can be defined as the uncontrolled growth of malignant PCs within...
2.
Radhakrishnan V, Kaifi J, Suvilesh K
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398206
Circulating tumor cells (CTCs) are cancer cells that slough off from the tumor and circulate in the peripheral blood and lymphatic system as micro metastases that eventually results in macro...
3.
Suvilesh K, Nussbaum Y, Radhakrishnan V, Manjunath Y, Avella D, Staveley-OCarroll K, et al.
Mol Cancer
. 2022 Mar;
21(1):73.
PMID: 35279152
Background: Circulating tumor cells (CTCs) are liquid biopsies that represent micrometastatic disease and may offer unique insights into future recurrences in non-small cell lung cancer (NSCLC). Due to CTC rarity...
4.
Avella Patino D, Radhakrishnan V, Suvilesh K, Manjunath Y, Li G, Kimchi E, et al.
Semin Cancer Biol
. 2021 Jun;
83:377-383.
PMID: 34182142
The epigenetic regulation of immune response involves reversible and heritable changes that do not alter the DNA sequence. Though there have been extensive studies accomplished relating to epigenetic changes in...
5.
Marudamuthu A, Bhandary Y, Fan L, Radhakrishnan V, MacKenzie B, Maier E, et al.
Sci Transl Med
. 2019 Dec;
11(522).
PMID: 31826982
Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic lung disease with a median 5-year survival of ~20%. Current U.S. Food and Drug Administration-approved pharmacotherapies slow progression of IPF, providing hope...
6.
Nagaraja M, Tiwari N, Shetty S, Marudamuthu A, Fan L, Ostrom R, et al.
Am J Pathol
. 2018 Sep;
188(10):2207-2222.
PMID: 30253845
Idiopathic pulmonary fibrosis (IPF) is a debilitating, incurable, and life-threatening disease. A cardinal feature of the pathogenesis of IPF is excessive extracellular matrix deposition attributable to proliferation of activated fibrotic...
7.
Radhakrishnan V, Kumar R, George D, Abraham G
Case Rep Transplant
. 2015 Sep;
2015:894786.
PMID: 26347845
Introduction. Renal transplantation has become the standard of care for patients with end stage renal disease. We present a rare case of an absent right sided iliac arterial system encountered...